Sponsor hub
GlaxoSmithKline clinical trial failures
Review 270 stopped clinical trials from GlaxoSmithKline, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 44 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OTHER/UNKNOWN
- 145
- OPERATIONAL
- 78
- EFFICACY/FUTILITY
- 26
- SAFETY
- 18
- REGULATORY
- 3
Notable sponsors
- GlaxoSmithKline
- 270
Related phases
- Phase I
- 110
- Phase II
- 83
- Phase III
- 50
- Phase IV
- 24
- Unknown
- 3
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Hepatitis B trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated as a strategic decision
Phase II Dermatitis, Atopic trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified.
Phase II Dermatitis, Atopic trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.
Phase I Leishmaniasis trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Further development of GSK3494245 has been halted based on assessment of clinical data indicating that predicted efficacious doses cannot be achieved in line with dosing requirements outlined in the target product profile for the proposed indication.
Phase II Idiopathic Pulmonary Fibrosis trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.
Phase I Hepatitis B, Chronic trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
Following the primary phase (24 weeks post last vaccination) the predefined efficacy endpoint was not met. Noting the lack of efficacy and with the objective to prioritize participants' safety GSK has decided on the early termination of the study.
Phase I Hematologic Diseases trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor decision to terminate the study due to strategic business consideration and not related to safety.
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Multiple Myeloma trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Pain trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.
Phase II Pain trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.
Phase I Systemic Lupus Erythematosus trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The trial was temporarily halted due to findings in new non-clinical studies necessitating further investigation.
Phase I Autoimmune Diseases trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Sponsor decision
Phase II Lung Cancer, Non-Small Cell trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Trial terminated by GSK for strategic reasons, after all participants completed treatment. This decision was not based on a safety concern
Phase II Neoplasms trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Due to low enrolment of participants
Phase I Tuberculosis trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
A decision to stop the study was made by the site and GSK project team based on pre-defined stopping criteria in the protocol
Phase III Respiratory Syncytial Virus Infections trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study.
Phase II Infections, Bacterial trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Business Decision
Phase I Leukemia, Myeloid, Acute trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.
Phase I Relapsed/Refractory Multiple Myeloma trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to lack of efficacy
Phase III Respiratory Syncytial Virus Infections trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study.
Phase I Macular Edema trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study was terminated as the study met the prespecified threshold for futility of less than (\<) 20 percentage (%), based on interim analysis (IA).
Phase III Neoplasms, Head and Neck trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The trial was stopped by the sponsor based on assessment of the clinical data
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
This study has been terminated due to meeting protocol defined futility.
Phase III Neoplasms, Head and Neck trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The trial was stopped by the sponsor based on assessment of the clinical data
Phase I Heart Failure trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
To allow for additional assessments from supplementary non-clinical activities.
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: SAFETY.
Primary investigator withdrew the participant due to an SAE
Phase II Anaemia trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study is terminated due to feasibility in recruitment.
Phase I Pain trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
This study was terminated due to meeting protocol defined futility.
Phase I Relapsed/Refractory Multiple Myeloma trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to lack of efficacy.
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated for reasons pertaining to feasibility
Phase III Arthritis, Rheumatoid trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Study is early terminated due to Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
Phase II Arthritis, Rheumatoid trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Cancelled Before Active
Phase II COVID-19 trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants
Phase I Colitis, Ulcerative trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Study terminated prior to FSFV for strategic business reasons.
Phase III Multiple Myeloma trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study has been terminated for reasons pertaining to feasibility
Phase III Arthritis, Rheumatoid trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
Phase I Leishmaniasis trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The trial was terminated early following strategic review after emergence of nonclinical data with a non-GlaxoSmithKline asset.
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Trial terminated due to internal review of clinical data in context of indication under investigation
Phase I Healthy Volunteers trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Internal sponsor decision to terminate project prematurely based on a waiver granted by Egypt EDA (Egyptian drug authority). No subjects were enrolled.
Phase I Healthy Volunteers trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Internal sponsor decision to terminate project prematurely based on a waiver granted by Egypt EDA (Egyptian drug authority). No subjects were enrolled.
Phase I Arthritis, Rheumatoid trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions
Phase I Solid Tumours trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
This study has been terminated due to meeting protocol defined futility.
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: SAFETY.
Overall benefit-risk profile did not support continuation of the study
Phase II Colitis, Ulcerative trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The trial was stopped based on the assessment of clinical data.
Phase III Respiratory Syncytial Virus Infections trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in this study.
Phase II Crohns Disease trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Internal sponsor decision to terminate project in Crohn's disease due to potential narrow therapeutic window. No subjects were enrolled
Phase I Neoplasms trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated following an internal review of the company's research and development portfolio
Phase II Pulmonary Disease, Chronic Obstructive trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Unfavourable benefit:risk
Phase I Herpes Simplex trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
To enable development of an enhanced version of the vaccine
Phase II Neoplasms, Breast trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Study termination due to negative Ph III of another study product from same technology platform.
Phase II Pulmonary Disease, Chronic Obstructive trial by GlaxoSmithKline. Stop reason: SAFETY.
Study terminated due to a change in the benefit-risk profile for danirixin in COPD.
Phase I Healthy Volunteers trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
Study terminated due to low probability of achieving a positive outcome on the primary endpoint.
Phase III Melanoma trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.
Phase IV Seizures trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate.
Phase III Lung Cancer, Non-Small Cell trial by GlaxoSmithKline. Stop reason: SAFETY.
The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.
Phase IV Epilepsy trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Arthritis, Rheumatoid trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The trial was terminated for strategic reasons following the emergence of new data.
Phase II Virus Diseases trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was stopped early due to lack of enrollment.
Phase II Asthma trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Post-Traumatic Stress Disorder trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
difficulty in achieving target enrollment numbers
Phase II Epilepsy trial by GlaxoSmithKline. Stop reason: REGULATORY.
Terminated after placing the study on hold at the request of the FDA
Phase I Inflammatory Bowel Diseases trial by GlaxoSmithKline. Stop reason: SAFETY.
Terminated due to non clinical toxicology findings and reduced safety margins.
Phase IV Herpes Genitalis trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Terminated
Phase I Multiple Sclerosis, Relapsing-Remitting trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Graves Ophthalmopathy trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.
Phase II Colitis, Ulcerative trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
SB-656933 is no longer being developed for ulcerative colitis.
Phase II Influenza trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.
Phase III Epilepsy trial by GlaxoSmithKline. Stop reason: SAFETY.
FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.
Phase IV Diabetes Mellitus trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Arthritis, Rheumatoid trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated following an internal review of the company's current research and development portfolio.
Phase II Diabetes Mellitus, Type 1 trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
A Phase 3 study recently reported and demonstrated that the dose of otelixizumab in OTX113390 is not effective.
Phase IV Diabetes Mellitus, Type 2 trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Early termination due to insufficient enrollment.
Phase II Lung Injury, Acute and Respiratory Distress Syndrome, Adult trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The study was terminated on the basis that protocol defined stopping criteria had been met.
Phase II Asthma trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Recruitment was terminated early before meeting target enrolment due to a high screen failure rate and the feasibility of completing the study in a timely way
Phase I Alzheimer's Disease trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Study objectives met so study concluded earlier than planned hence we terminated the study.
Phase I Colitis, Ulcerative trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
GSK has elected to terminate development principally as a result of the statin drug-drug interaction (DDI) study.
Phase II Melanoma trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients.
Phase II Pulmonary Disease, Chronic Obstructive trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Terminated based on lack of efficacy seen in participants taking danirixin in dose ranging study and Sponsor decision to stop development of danirixin for COPD
Phase II Neoplasms, Pancreatic trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was terminated following an internal review of the company's current research and development portfolio.
Phase III Obstetric Labour, Premature trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
The study was stopped due to the feasibility of recruiting the study in a timely manner
Phase III Obstetric Labour, Premature trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Asset terminated by PIB
Phase I Pulmonary Disease, Chronic Obstructive trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The trial is terminated before investigation of repeat escalating doses as these will be conducted with the new formulation instead.
Phase I Pancreatitis, Acute Necrotizing trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The study was terminated as relationship between GSK3335065 and ventricular tachycardia could not be excluded.
Phase IV Pulmonary Disease, Chronic Obstructive trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.
Unknown Acute Lung Injury trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
Study stopped early following termination of associated clinical development program (due to lack of efficacy)
Phase I Postpartum Hemorrhage trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Inability to reliably measure plasma oxytocin levels during third stage labour, regardless of administration method (intramuscular or inhaled).
Phase II Dermatitis, Atopic trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
Study reached pre-determined futility criteria following interim analysis. No safety concerns were noted.
Phase I Cancer trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
The maximal dose and schedule attained with GSK2816126 has shown insufficient evidence of clinical activity, and does not justify further clinical investigation
Phase I Cancer trial by GlaxoSmithKline. Stop reason: SAFETY.
In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile.
Phase I Healthy Volunteers trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
Study terminated for technical feasibility, operational considerations and futility in line with pre-specified criteria.
Phase I Carcinoma, Small Cell trial by GlaxoSmithKline. Stop reason: SAFETY.
The risk benefit in relapsed refractory SCLC does not favor continuation of the study
Phase IV Human Papillomavirus Infection Leading to Cervical Cancer trial by GlaxoSmithKline. Stop reason: OPERATIONAL.
GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study.
Phase II Neoplasms trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Internal decision, study will be replaced with a larger monotherapy trial
Phase II Amyloidosis trial by GlaxoSmithKline. Stop reason: SAFETY.
Change in benefit/risk profile
Phase II Hypertension, Pulmonary trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Ongoing juvenile rat toxicology studies.
Phase I Cough trial by GlaxoSmithKline. Stop reason: EFFICACY/FUTILITY.
Study terminated due to lack of efficacy of GSK2798745 in chronic cough.
Phase I Amyloidosis trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
A new study will be initiated in order to specifically investigate cardiac safety
Phase I Amyloidosis trial by GlaxoSmithKline. Stop reason: SAFETY.
Change in benefit/risk profile.
Phase I Idiopathic Pulmonary Fibrosis trial by GlaxoSmithKline. Stop reason: OTHER/UNKNOWN.
Sufficient information was gathered from cohort 1 to terminate the study without proceeding to optional cohort 2.